The latest KDIGO guidelines have adopted a holistic approach to DKD therapies and recommended optimizing renin-angiotensin system inhibitors to the maximum toleraated dose in patients with (G1–G4, A2–A3; Fig. 1) and starting sodium-glucose cotransporter 2 inhibitors for treating patients with T2DM and eGFR ≥ 20 ml/min per 1.73 m2. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.